FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Launched by INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) · Apr 2, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of PET scans in patients with Marginal Zone Lymphoma (MZL). The goal is to see how well PET scans help in staging the disease, assessing how well treatment is working, and predicting patient outcomes. The study will look back at patients who have already had PET scans as part of their diagnosis or treatment, and it will analyze these scans alongside other tests like CT scans and lab results to understand their effectiveness.

To participate in this trial, you need to be an adult over 18 years old and have a confirmed diagnosis of one of the specific types of MZL. Additionally, your medical records should include details about your treatment and follow-up, and you must have had the required imaging tests. Importantly, this study does not require any new scans or procedures; it will only use information and scans that have already been done. If you join the trial, you will help researchers learn more about how PET scans can improve the care and treatment of MZL patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. One of the following subtypes of Histology confirmed Indolent non-follicular B-cell lymphoma:
• • Splenic MZL (bone marrow histology and/or splenic tissue);
• • Extranodal MZL or MALT (tissue biopsy);
• • Nodal MZL (lymph node biopsy).
• • 2. Age over 18.
• • 3. Availability of details on clinical presentation, treatment details and results, and on follow-up.
• • 4. Execution of PET at diagnosis or/and at end of treatment or/and at relapse.
• • 5. Execution of CT scan with iodine contrast medium at diagnosis and at assessment of response.
• • 6. Patients with histologically confirmed marginal zone lymphomas according to the current WHO classification are registered in the study. Diagnosis based on tru-cut core-needle biopsies are permitted in the study.
• • 7. Written informed consent.
• Exclusion Criteria:
• • 1. Patients with a diagnosis of Non Hodgkin Lymphoma other than MZL.
• • 2. Scans images not available for whatever reason.
• • 3. Cases diagnosed on fine needle aspiration cytology only.